Hematological Oncology

Anna Panovská, Lucie NĚmcová, Lucie Nekvindová, Martin Špaček, Martin Šimkovič, Tomáš Papajík, Martin Brejcha, Daniel Lysák, Jana Zuchnická, Jan Novák, David Starostka, Hynek Poul, Filip Vrbacký, Pavel Vodárek, Renata Urbanová, Karla Plevová, Šárka Pospíšilová, Stanislava Mašlejová, Yvona Brychtová, Eva KoriŤáková, Lukáš Smolej, Michael Doubek
Until recently, a combination of anti-CD20 antibody plus less intensive chemotherapy was a standard of care in elderly population with previously untreated chronic lymphocytic leukemia (CLL). The aim of this observational study was to retrospectively assess efficacy and safety of obinutuzumab+chlorambucil (G-Clb), rituximab+chlorambucil (R-Clb), and bendamustine + rituximab (BR) given as the frontline therapy within routine practice. The final analysed dataset included 398 consecutive CLL patients from 10 hematology centres cooperating within the Czech CLL Study Group: 63 treated with G-Clb, 78 with R-Clb, and 257 with BR...
May 13, 2020: Hematological Oncology
Xiaofei Ye, Fangyuan Hu, Yinghong Zhai, Yingyi Qin, Jinfang Xu, Xiaojing Guo, Jia He
Immune checkpoint inhibitors (ICIs) have shown remarkable clinical effects in many cancer types. However, ICIs could also induce severe organ system toxicities, including those of the hematological system. The present study aimed to extensively characterize the hematological toxicities of ICIs immunotherapy. Data were extracted from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database from January 1, 2014 to March 31, 2019. Disproportionality analysis, including information component (IC) and reporting odds ratio (ROR) were used to detect potential disproportionality signal...
May 8, 2020: Hematological Oncology
Wolfgang Knauf, Wolfgang Abenhardt, Hans Rainer Slawik, Ute Bückner, Burkhard Otremba, Annette Sauer, Mark-Oliver Zahn, Natalie Wetzel, Anja Kaiser-Osterhues, Leonora Houet, Norbert Marschner
Waldenström's macroglobulinaemia (WM) is a rare indolent B-cell lymphoma for which only little prospective phase III evidence exists. Thus, real world data are important to provide insight into treatment and survival. We present here data on choice and outcome of systemic treatment of patients with WM treated in German routine practice. In total, 139 patients with WM who had been documented in the prospective clinical cohort study Tumour Registry Lymphatic Neoplasms (NCT00889798) were included into this analysis...
May 8, 2020: Hematological Oncology
Andrés J M Ferreri, Marianna Sassone, Piera Angelillo, Francesco Zaja, Alessandro Re, Alice Di Rocco, Michele Spina, Alberto Fabbri, Caterina Stelitano, Maurizio Frezzato, Stefano Volpetti, Renato Zambello, Chiara Rusconi, Daniela De Lorenzo, Eloise Scarano, Annalisa Arcari, Giovanni Bertoldero, Alessandro Nonis, Teresa Calimeri, Salvatore Perrone, Caterina Cecchetti, Vittoria Tarantino, Sara Steffanoni, Marco Foppoli, Fabio Ciceri, Maurilio Ponzoni
We report final results of a phase II trial addressing efficacy and feasibility of lenalidomide maintenance in patients with chemo-sensitive relapse of diffuse large B-cell lymphoma (DLBCL) not eligible for or failed after autologous stem cell transplantation (ASCT). Patients with relapsed DLBCL who achieved at least a partial response to salvage chemoimmunotherapy were enrolled and treated with lenalidomide 25 mg/day for 21 of 28 days for two years or until progression or unacceptable toxicity. Primary endpoint was one-year PFS...
May 1, 2020: Hematological Oncology
Tomas Jelinek, Tereza Popkova, Juraj Duras, Jana Mihalyova, Michal Kascak, Katerina Benkova, Hana Plonkova, Lucie Cerna, Zdenek Koristek, Michal Simicek, Roman Hajek
No abstract text is available yet for this article.
April 23, 2020: Hematological Oncology
Min Xiao, Junpeng Lin, Tingting Xiao, Yan Lin, Yong Ye
This study aimed to evaluate the incidence and prognosis of primary cardiac lymphoma (PCL) by using the Surveillance, Epidemiology, and End Results Program (SEER) database. Patients diagnosed with PCL and the disease incidence in the SEER database from 1975 to 2016 were included. Overall survival (OS) and cause-specific survival (CSS) curves were calculated using the Kaplan-Meier method and compared by the log-rank test. Univariate and multivariable Cox proportional hazard regression analyses were used to identify associations with outcome measures...
April 20, 2020: Hematological Oncology
Johanna Flach, Evgenii Shumilov, Gertrud Wiedemann, Naomi Porret, Inna Shakhanova, Susanne Bürki, Myriam Legros, Raphael Joncourt, Thomas Pabst, Ulrike Bacher
Relapse of acute myeloid leukemia (AML) remains the major determinant of outcome. A number of molecularly directed treatment options have recently emerged making comprehensive diagnostics an important pillar of clinical decision making at relapse. Acknowledging the high degree of individual genetic variability at AML relapse, next-generation sequencing (NGS) has opened the opportunity for assessing the unique clonal hierarchy of individual AML patients. Knowledge on the genetic makeup of AML is reflected in patient customized treatment strategies thereby providing improved outcomes...
April 19, 2020: Hematological Oncology
Francesca Palandri, Massimo Breccia, Mario Tiribelli, Massimiliano Bonifacio, Giulia Benevolo, Alessandra Iurlo, Elena M Elli, Gianni Binotto, Alessia Tieghi, Nicola Polverelli, Bruno Martino, Elisabetta Abruzzese, Micaela Bergamaschi, Florian H Heidel, Francesco Cavazzini, Monica Crugnola, Costanza Bosi, Alessandro Isidori, Giuseppe Auteri, Dorian Forte, Roberto Latagliata, Davide Griguolo, Daniele Cattaneo, Malgorzata Trawinska, Daniela Bartoletti, Mauro Krampera, Gianpietro Semenzato, Roberto M Lemoli, Antonio Cuneo, Francesco Di Raimondo, Nicola Vianelli, Michele Cavo, Giuseppe A Palumbo
The impact of ruxolitinib therapy on evolution to blast phase (BP) in patients with myelofibrosis (MF) is still uncertain. In 589 MF patients treated with ruxolitinib, we investigated incidence and risk factors for BP and we described outcome according to disease characteristics and treatment strategy. After a median follow-up from ruxolitinib start of 3 years (range 0.1-7.6), 65 (11%) patients transformed to BP during (93.8%) or after treatment. BP incidence rate was 3.7 per 100 patient-years, comparably in primary and secondary MF (PMF/SMF) but significantly lower in intermediate-1 risk patients (2...
April 9, 2020: Hematological Oncology
Anne-Cécile Gauchy, Lukshe Kanagaratnam, Anne Quinquenel, Baptiste Gaillard, Cyrielle Rodier, Sophie Godet, Alain Delmer, Eric Durot
Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non-Hodgkin lymphoma. The prevalence of hypercalcemia in this neoplasm and its prognostic significance is unclear. We retrospectively evaluated the prevalence of hypercalcemia at diagnosis of DLBCL and explored associations of hypercalcemia with clinical factors and outcome. Outcome was assessed using event-free survival at 24 months (EFS24). A total of 305 patients (248 de novo DLBCL and 57 transformed indolent lymphomas) diagnosed between 2006 and 2018 in Reims were analyzed...
April 9, 2020: Hematological Oncology
Michael Roost Clausen, Sinna Pilgaard Ulrichsen, Maja Bech Juul, Christian B Poulsen, Brian Østergaard, Per Trøllund Pedersen, Jakob Madsen, Robert Schou Pedersen, Pär Lars Josefsson, Jette Sønderskov Gørløv, Mette Nørgaard, Francesco d'Amore
Infections during first-line therapy for DLBCL are often associated with chemotherapy dose reductions and increased mortality. Systemic infections have also been suggested as beneficial promotors of immunological responses. However, whether there is an association between the timing of an infectious episode and outcome during treatment has not yet been clarified. We investigated how the occurrence and timing of infectious episodes during the 1st line of treatment for 'de novo' DLBCL influenced patient outcome...
April 2, 2020: Hematological Oncology
Akihito Nagata, Yusuke Kanemasa, Yuki Sasaki, Shohei Nakamura, Toshihiro Okuya, Chikako Funasaka, Akihiko Kageyama, Tatsu Shimoyama, Yasushi Omuro
The Controlling Nutritional Status (CONUT) score is a nutritional index calculated from serum albumin and total cholesterol levels and lymphocyte counts. Its role in predicting clinical outcomes of diffuse large B-cell lymphoma (DLBCL) has not been evaluated. In this retrospective study, data from 476 patients with DLBCL were analyzed. The cutoff value of the CONUT score was set as 4. CONUT score significantly stratified the overall survival (OS) and the progression-free-survival (PFS) (5-year OS, 49.0 % vs...
March 29, 2020: Hematological Oncology
Jeff Hosry, Roberto N Miranda, Felipe Samaniego, Georgios Angelidakis, Harrys A Torres
Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin lymphoma. It has been hypothesized that chronic hepatitis C virus (HCV) infection stimulates IGH-BCL2 clone proliferation, leading to development of FL. Furthermore, regression of FL after antiviral treatment without chemotherapy has been reported in HCV-infected patients. To clarify the relationship between HCV and FL, we compared the prevalence of IGH-BCL2 translocation and other clinicopathologic characteristics between HCV-infected and HCV-uninfected FL patients and determined the impact of HCV eradication on the oncologic outcomes of HCV-infected FL patients...
March 20, 2020: Hematological Oncology
Rintaro Ohe, Hong-Xue Meng, Akane Yamada, Naing Ye Aung, Takanobu Kabasawa, Yuka Tamura, Aya Utsunomiya, Nobuyuki Tamazawa, Ichiro Kawamura, Takumi Kitaoka, Kazushi Suzuki, Ryo Yanagiya, Tomomi Toubai, Kenichi Ishizawa, Mitsunori Yamakawa
Follicular lymphoma (FL) has a meshwork of follicular dendritic cells (FDCs). We previously demonstrated the presence of estrogen receptor alpha (ERα)+ CD23+ FDCs in grades 1-2 FL. The significance of FDCs as a prognostic factor in FL remains unknown. The current study aimed to compare clinicopathological features, including prognosis, between FL with and without ERα+ FDCs. This study evaluated the clinicopathological significance of ERα expression in 70 FL patients by immunostaining. The presence of ERα mRNA on FDCs from 5 FL patients was confirmed by CD21/ERα double staining (immunohistochemistry and in situ hybridization)...
March 20, 2020: Hematological Oncology
Natalia P Schütz, Paola Ochoa, Patricio Duarte, Guillermina Remaggi, Sebastián Yantorno, Ariel Corzo, Soledad Zabaljauregui, Claudia Shanley, Sergio Lopresti, Sergio Orlando, Verónica Verri, Luis Quiroga, Carlos A García, Vanesa Fernández, Dorotea Fantl
Data about treatment outcomes and toxicity in Latin America are scarce. There are differences with central countries based on access to healthcare system and socioeconomic status. Argentinean Society of Hematology recommends bortezomib-based triplets for induction treatment of transplant eligible newly diagnosed multiple myeloma patients. Most common options are CyBorD (cyclophosphamide, bortezomib and dexamethasone) and VTD (bortezomib, thalidomide and dexamethasone). Main goal of our retrospective, multicentric study was to compare very good partial response rate (VGPR) or better after induction treatment in a real-world setting in Argentina...
March 20, 2020: Hematological Oncology
Chang-Kyu Oh, Mihyang Ha, Myoung-Eun Han, Hye Jin Heo, Kyungjae Myung, Yoonsung Lee, Sae-Ock Oh, Yun Hak Kim
Accurate prediction of malignancies is important in choosing therapeutic strategies. Although there are many genetic and cytogenetic prognostic factors for acute myeloid leukemia (AML), prognosis is difficult to predict because of the heterogeneity of AML. Prognostic factors, including messenger RNA (mRNA) expression, have been determined for other malignancies, but not for AML. A total of 402 patients from The Cancer Genome Atlas, GSE12417 (GPL96, 97), and GSE12417 (GPL570) were included in this study. In Kaplan-Meier curve analyses, high expression of family with sequence similarity 213 member A (FAM213A), which activates antioxidant proteins, was associated with worse prognosis of AML...
March 3, 2020: Hematological Oncology
Davide Facchinelli, Esteban Ciliberti, Georg Stüssi, Luca Ceriani, Emanuele Zucca
No abstract text is available yet for this article.
April 2020: Hematological Oncology
Stefan Hatzl, Florian Posch, Alexander Deutsch, Christine Beham-Schmid, Herbert Stöger, Hildegard Greinix, Martin Pichler, Peter Neumeister, Katharina T Prochazka
Overexpression of bcl-2 and c-myc are defining features of double-expressor-lymphoma (DEL) but may also occur separately in patients with primary central nervous system lymphoma (PCNSL). Despite all progress in optimizing treatment regimen, there is lack of sufficient risk stratification models. Here, we first describe the relationship between DEL biology, the National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI), treatment response, disease progression, and mortality in PCNSL. In this study, we determined c-myc and bcl-2 status immunohistochemically in samples of 48 patients with newly diagnosed PCNSL and followed these patients for a median interval of 6...
February 26, 2020: Hematological Oncology
Marta Lionetti, Marzia Barbieri, Vanessa Favasuli, Elisa Taiana, Sonia Fabris, Chiara Favoino, Gabriella Ciceri, Serena Matis, Monica Colombo, Rosanna Massara, Gianluigi Reda, Massimo Gentile, Valeria Spina, Davide Rossi, Luca Baldini, Gianluca Gaidano, Franco Fais, Manlio Ferrarini, Fortunato Morabito, Giovanna Cutrona, Antonino Neri
No abstract text is available yet for this article.
February 25, 2020: Hematological Oncology
Wang Bingjie, Wang Lihong, Shi Yongjin, Liu Huihui, Ou Jinping, Cen Xi'nan
The efficacy and safety of Epstein-Barr virus (EBV) specific antigen peptide-activated cytotoxic T cells (CTLs) in the treatment of refractory or recurrent angioimmunoblastic T cell lymphoma(AITL)was determined in this prospective one-arm clinical study. 7 males and 2 females were enrolled with a median age of 70 years. The tumor stages were all stage III-IV. All patients had group B symptoms and IPI scores of 3-5 points. All patients received chemotherapy before CTLs infusion which the median chemotherapy cycle was 3...
February 21, 2020: Hematological Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"